Sagimet Biosciences, Inc. Class A AI Stock Analysis
Want to see SGMT full AI Analyst Report?
Sagimet Biosciences, Inc. Class A (SGMT) AI Stock Analysis
Sagimet Biosciences, Inc. Class A
(NASDAQ:SGMT)
SGMT’s score is held back most by weak financial performance (minimal revenue, large ongoing losses, and persistent cash burn) despite a strengthened, low-debt balance sheet. Offsetting this, technicals are supportive with the stock trading above key moving averages and positive momentum, and corporate events are favorable with Phase 3/regulatory progress and substantial new financing improving funding runway. Valuation contributes only moderately given the negative P/E and lack of dividend yield data.
Sagimet Biosciences, Inc. Class A (SGMT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $712.56M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.24M
- Price to Earnings (P/E)
- -8.6
- Beta (1Y)
- 2.64
- Revenue Growth
- ―
- EPS Growth
- 33.38%
- Country
- US
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Sagimet Biosciences, Inc. Class A Business Overview & Revenue Model
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United...
How the Company Makes Money
Sagimet Biosciences does not have publicly known material recurring revenue from marketed products; as a clinical-stage biotechnology company, its ability to generate revenue is primarily tied to financing and partnering activities rather than produc...
Sagimet Biosciences, Inc. Class A Financial Statement Overview
Summary
Overall fundamentals are mixed: the balance sheet is a clear strength with very low leverage (debt-to-equity near zero) and meaningfully improved equity, but the company remains pre-commercial with minimal revenue, persistent and widening net losses (TTM net loss about -$53.3M), and sustained negative operating/free cash flow indicating ongoing cash burn and funding needs.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 2.00M | 0 | 0 |
| Gross Profit | -21.57M | 0 | 0 | 2.00M | 0 | 0 |
| EBITDA | -55.94M | -51.04M | -45.57M | -27.88M | -30.37M | -24.44M |
| Net Income | -53.32M | -51.04M | -45.57M | -27.88M | -30.50M | -24.44M |
Balance Sheet | ||||||
| Total Assets | 282.09M | 116.48M | 160.26M | 96.72M | 33.03M | 59.03M |
| Cash, Cash Equivalents and Short-Term Investments | 236.40M | 113.12M | 151.25M | 94.90M | 32.34M | 56.73M |
| Total Debt | 2.02M | 78.00K | 78.00K | 65.00K | 211.00K | 348.00K |
| Total Liabilities | 39.91M | 5.10M | 4.45M | 5.65M | 219.98M | 217.29M |
| Stockholders Equity | 242.18M | 111.38M | 155.81M | 91.06M | -186.95M | -158.26M |
Cash Flow | ||||||
| Free Cash Flow | -43.25M | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Operating Cash Flow | -43.25M | -45.65M | -42.44M | -23.77M | -24.49M | -21.71M |
| Investing Cash Flow | -72.69M | 4.56M | -61.68M | 12.58M | -32.01M | 0 |
| Financing Cash Flow | 369.81M | 275.00K | 104.82M | 86.17M | -73.00K | 9.74M |
Sagimet Biosciences, Inc. Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGMT, the sentiment is Neutral. The current price of 9.85 is below the 20-day moving average (MA) of 10.17, below the 50-day MA of 9.86, and above the 200-day MA of 7.73, indicating a neutral trend. The MACD of 0.28 indicates Negative momentum. The RSI at 51.03 is Neutral, neither overbought nor oversold. The STOCH value of 58.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SGMT.
Sagimet Biosciences, Inc. Class A Risk Analysis
Sagimet Biosciences, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Sagimet Biosciences, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksSagimet Biosciences, Inc. Class A Peers Comparison
Overall Rating
SGMT58Neutral
AVIR48Neutral
CDXS45Neutral
CABA41Neutral
BDTX39Underperform
TRDA39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | $712.56M | -8.57 | -29.95% | ― | ― | 33.38% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $330.85M | -2.13 | -69.92% | ― | ― | -10.43% | |
| 45Neutral | $116.17M | -5.43 | -43.24% | ― | 66.89% | 73.74% | |
| 41Neutral | $239.45M | -0.78 | -106.78% | ― | ― | 43.51% | |
| 39Underperform | $87.93M | -1.95 | -43.99% | ― | -100.00% | -302.37% | |
| 39Underperform | $195.75M | -1.32 | -64.00% | ― | -93.54% | -53.55% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SGMT | Sagimet Biosciences, Inc. Class A | 9.85 | 2.00 | 25.48% | |
| CDXS | Codexis | 1.07 | -0.55 | -33.95% | |
| CABA | Cabaletta Bio, Inc. | 1.02 | -1.22 | -54.46% | |
| BDTX | Black Diamond Therapeutics, Inc. | 1.44 | -2.45 | -62.98% | |
| AVIR | Atea Pharmaceuticals, Inc. | 3.96 | 0.81 | 25.71% | |
| TRDA | Entrada Therapeutics Inc | 4.96 | -3.77 | -43.18% |
Sagimet Biosciences, Inc. Class A Corporate Events
Sagimet Biosciences Reports Third-Quarter Financial Results and R&D Growth
PositiveOn November 12, 2026, Sagimet reported a net loss of $19.1 million for the third quarter and $43.8 million for the first nine months, compared with $12.9 million and $41.5 million, respectively, a year earlier. Research and development expense rose t...
Sagimet Biosciences Highlights Progress in Acne FASN Pipeline
PositiveOn October 22, 2026, Sagimet Biosciences updated its investor slide presentation to highlight progress across its FASN inhibitor pipeline, led by denifanstat for moderate to severe acne. The company emphasized its experienced management team and diff...
Sagimet Biosciences Announces Major Equity Financing Agreement
PositiveOn September 30, 2026, Sagimet Biosciences Inc. entered into an underwriting agreement for an underwritten offering of 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants to purchase up to 2,750,010 shares at $9.9999...
Sagimet Reports Strong Phase 3 Acne Trial Results
PositiveOn September 30, 2026, Sagimet Biosciences reported positive 52-week results from the Phase 3 ASC40-304 open-label extension trial of denifanstat in patients with moderate to severe acne vulgaris in China, showing further improvements in lesion count...
Sagimet Wins FDA Clearance for Phase 3 Acne Trial
PositiveOn August 13, 2026, Sagimet Biosciences Inc. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for denifanstat. The agency issued a “Study May Proceed” letter, allowing the company to begin a Phase...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
